Clinical Trials Logo

Encephalitis Autoimmune clinical trials

View clinical trials related to Encephalitis Autoimmune.

Filter by:
  • None
  • Page 1

NCT ID: NCT06388161 Recruiting - Epilepsy Clinical Trials

Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology

Start date: August 1, 2023
Phase:
Study type: Observational [Patient Registry]

Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage. It is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.

NCT ID: NCT04653571 Completed - Clinical trials for Paraneoplastic Syndromes

CASPR2 Encephalitis Initial Symptoms

iniCASPR2
Start date: January 11, 2021
Phase:
Study type: Observational

Auto-immune encephalitides involve auto-antibodies targeting the central nervous system, and particularly the synapse and its structure, such as protein CASPR2. CASPR2 antibody-associated auto-immune encephalitides lead to an inflammation of the limbic system and generate focal temporal seizures and cognitive impairment. Most patients are initially hospitalized because of the temporal seizures (Joubert et al., JAMA Neurology 2016). However, many already show at that time cognitive impairment, which has failed to elicit the appropriate investigations, therefore delaying the diagnosis. The study will hence investigate precisely the initial, sometimes neglected, clinical symptoms and those leading to the diagnosis, in the cohort of patients suffering from a CASPR2 antibody-associated encephalitis, from the French reference center on paraneoplastic neurological diseases and autoimmune encephalitis. This way, the study aims to delineate the symptoms that should trigger suspicions of a CASPR2 antibody-associated encephalitis